The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | M | Musculo-skeletal system | |
| 2 | M05 | Drugs for treatment of bone diseases | |
| 3 | M05B | Drugs affecting bone structure and mineralization | |
| 4 | M05BC | Bone morphogenetic proteins | |
| 5 | M05BC02 | Eptotermin alfa |
| Active Ingredient | Description | |
|---|---|---|
| Eptotermin alfa |
Eptotermin alfa, the active substance, initiates bone formation through the induction of cellular differentiation in mesenchymal cells, which are recruited to the implant site from bone marrow, periosteum and muscle. Once bound at the cell surface, the active substance induces a cascade of cellular events leading to the formation of chondroblasts and osteoblasts, which play a key role in the bone formation process. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| OSIGRAFT Powder for suspension for implantation | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
